---
title: "Piper Sandler 维持对 NeoGenomics（NEO）的买入评级"
description: "根据 TipRanks 的数据，Westenberg 是一位 4 星分析师，平均回报率为 7.3%，成功率为 49.79%。Westenberg 覆盖医疗保健行业，关注的股票包括 GeneDx Holdings、Exact Sciences 和 Neogen。目前，分析师对 NeoGenomics 的共识评级为适度买入，平均目标价为 10.43 美元"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/259911344.md"
published_at: "2025-10-03T15:45:10.000Z"
---

# Piper Sandler 维持对 NeoGenomics（NEO）的买入评级

> 根据 TipRanks 的数据，Westenberg 是一位 4 星分析师，平均回报率为 7.3%，成功率为 49.79%。Westenberg 覆盖医疗保健行业，关注的股票包括 GeneDx Holdings、Exact Sciences 和 Neogen。目前，分析师对 NeoGenomics 的共识评级为适度买入，平均目标价为 10.43 美元

根据 TipRanks 的数据，Westenberg 是一位四星分析师，平均回报率为 7.3%，成功率为 49.79%。Westenberg 覆盖医疗保健行业，专注于 GeneDx Holdings、Exact Sciences 和 Neogen 等股票。

目前，分析师对 NeoGenomics 的共识评级为适度买入，平均目标价为 10.43 美元。

### Related Stocks

- [NEO.US - Neogenomics](https://longbridge.com/zh-CN/quote/NEO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection \| NEO Stock News | NeoGenomics, Inc. has launched PanTracer Pro, a new integrated testing approach aimed at improving the selection of ther | [Link](https://longbridge.com/zh-CN/news/275753736.md) |
| 165,890 Shares in NeoGenomics, Inc. $NEO Purchased by Y Intercept Hong Kong Ltd | Y Intercept Hong Kong Ltd acquired 165,890 shares of NeoGenomics, Inc. (NASDAQ: NEO) valued at approximately $1.28 milli | [Link](https://longbridge.com/zh-CN/news/274422182.md) |
| ZAWYA-PRESSR: Healthcare leaders call for greater strategic alignment between capital investment and health system strategy at WHX | Global healthcare leaders gathered at the World Health Expo (WHX) to discuss the need for strategic alignment between ca | [Link](https://longbridge.com/zh-CN/news/275449733.md) |
| Jorie AI Shares a Live Case Study on the Inevitable Future of Healthcare AI at ViVE 2026 | Jorie AI showcased its autonomous healthcare AI solutions at ViVE 2026, emphasizing the need for AI to operate effective | [Link](https://longbridge.com/zh-CN/news/275497445.md) |
| Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS) | Evercore ISI analyst Elizabeth Anderson maintained a Buy rating on CVS Health (CVS) with a price target of $100.00. Ande | [Link](https://longbridge.com/zh-CN/news/275622408.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。